Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from OncoSil Medical Ltd ( (AU:OSL) ) is now available.
OncoSil Medical has had Spanish multi-centre clinical data on its OncoSil pancreatic cancer device accepted for poster presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago. The study of 51 patients with unresectable locally advanced pancreatic cancer treated in Spanish centres reported a favourable safety profile, with only two device-related adverse events and a notable rate of patients later becoming eligible for surgery.
Investigators observed that 13.7% of initially unresectable patients underwent surgery, including five with complete tumour margin clearance, while median progression-free survival reached 8.5 months and median overall survival 15.6 months after OncoSil treatment. A separate Spanish case report in Cureus described a patient who, after receiving OncoSil plus chemotherapy without device-related complications, achieved disease stabilisation that enabled successful surgical resection and long-term survival, underscoring Spain’s leadership in adopting the therapy and reinforcing OncoSil’s clinical credibility in a challenging cancer indication.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is an Australian medical device company specialising in localised radiation treatments for patients with unresectable locally advanced pancreatic cancer. Its lead product, the OncoSil device, delivers phosphorus-32 microparticles via endoscopic ultrasound to target pancreatic tumours, with Spain emerging as a key market for routine clinical adoption.
Average Trading Volume: 73,874
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$16.12M
See more insights into OSL stock on TipRanks’ Stock Analysis page.